You are here: Industry Insights > Autoimmune diseases

News List

10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH PharmaSources
November 15, 2023
InnoCare Pharma,announced today that 10 studies from InnoCare's oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases B3C newswire
November 16, 2023
SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline.
Maxion Therapeutics Awarded £2 Million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-To-Treat" Autoimmune Diseases PharmaSources
April 20, 2023
Maxion therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “Hard-To-Treat" autoimmune diseases.
First Signs of MS May Often Go Undiagnosed drugs
June 28, 2021
Early symptoms of multiple sclerosis may commonly be missed for years before the right diagnosis is made, a new study suggests.
Scipher Applies Spectra™ Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies b3cnewswire
May 21, 2021
Scipher Medicine，today announced the launch of Scipher Therapeutics, focused on discovering new targets and drugs for patients not responding to approved therapies in the market.
Exagen to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection americanpharmaceuticalreview
November 11, 2020
Exagen announced a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19.
Lilly, Sitryx Enter Autoimmune Alliance contractpharma
April 01, 2020
To develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
BioMed X Starts New Research Program in Autoimmune Diseases with Merck b3cnewswire
January 17, 2020
BioMed X announced today the start of a new joint research group in collaboration with Merck. With this new group, BioMed X and Merck extend their ongoing collaboration to a total of six joint research projects at the BioMed X Innovation Center in Heidelb
Parvus Therapeutics, Genetech collaborate for autoimmune diseases biospectrumasia
May 20, 2019
Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales
Novel treatments offer new hope for patients with autoimmune disease worldpharmanews
March 06, 2019
Autoimmune diseases, including type 1 diabetes and multiple sclerosis, arise when the body's immune cells attack itself.

Previous page 1 2 Next page